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  “Failure defeats losers, failure inspires winners” 
    Robert T. Kiyosaki 
ABSTRACT 
Background: Malignancies emerging in the nasal cavity and the paranasal sinuses are 
rare and accounts for 5% of all head and neck malignancies and 0.1% of all 
malignancies in Sweden. The incidence of sinonasal malignancy (SNM), except 
sinonasal malignant melanoma (SNMM), has been reported to decrease since 1960 in 
Sweden. Despite similar improvement in the prognosis of other malignancies, treatment 
of SNM still yields a poor survival outcome. 
  
About 1–2% of all malignant melanomas originate from mucosal membranes in the 
genitourinary, digestive and the respiratory regions, whereas mucosal melanomas are 
most frequently located in the nasal cavity, followed by sites in paranasal sinuses in the 
head and neck region. The incidence of cutaneous malignant melanoma (CMM) 
continues to increase in many parts of the world, possibly due mainly to the effects of 
sun-related behaviour; however, the incidence of mucosal melanomas such as vulvar 
and ano-rectal melanoma display a more complicated pattern with a stable or 
decreasing incidence rate. We now know that the incidence of SNMM is increasing in 
Sweden, as we have documented one of the largest consecutively studied SNMM 
groups in the world. Nevertheless, the underlying mechanism remains unclear. 
The treatment options for these patients have remained the same over the years; mainly 
radical surgery followed by radiotherapy. Alternatively, recent molecular-targeted 
therapy has become available for sub-groups of patients with malignant melanomas. 
Such therapeutic advances stress the importance of investigating the aetiology and 
molecular characteristics of SNMM, which are not yet well. 
 
 
Aims: Given the rarity of SNM and SNMM, relevant knowledge is limited. Therefore, 
the overall aim of this thesis was to examine the clinical characteristics and features of 
SNMM and SNM and to determine the occurrence of molecular alterations. They 
include KIT, NRAS and BRAF mutation frequencies and mutation frequency of the 
TERT (Telomerase Reverse Transcriptase) promotor gene in SNMM. 
 
 
Results: In the first project, we identified 3221 patients from the Swedish National 
Cancer Registry diagnosed with primary malignancies arising from the nasal cavity, 
paranasal sinuses, or both, during the period 1960 through 2011. The anatomical site, 
gender and age, incidence and survival were scrutinized. We found that the incidence 
of sinonasal malignancies decreased except for SNMM and adenoid cystic cancer 
during the study period. More than 50% of these malignancies involved the nasal 
cavity. The five-year relative survival was highest for patients with adenoid cystic 
cancer followed by adenocarcinoma. Those with SNMM and undifferentiated 
carcinoma had the poorest prognosis.  
 
 
 
 
In the second project we identified 186 SNMM patients during the period 1960 through 
2000 in Sweden from the National Swedish Cancer Registry (SCR). We investigated 
the incidence, gender, age, primary anatomical sites, geographic distribution, treatment 
and survival. 
In this population the incidence of SNMM increased during the study period. The 
incidence for females was higher than for males, and the incidence increased with age 
for both genders. We found that about 70% of the tumours were clinically described as 
amelanotic. Surgery was the most common primary treatment. The five-year disease-
specific survival rates were poor for both genders, but females had a better survival 
than males. The survival rate improved for both genders during the study period, 
regardless of therapeutic strategy. We conclude that the incidence of SNMM in Sweden 
increased significantly from 1960 through 2000 but not as rapidly as that of CMM.  
 
 
In the third project, we analysed 56 primary SNMMs, the largest number, as far as we 
know, for mutations in KIT (exons 11, 13 and 17), NRAS (exons 1 and 2) and BRAF  
(exon 15) identified by using direct sequencing. Twelve of the 56 (21%) tumours 
contained mutations in these oncogenes, 2 tumours harboured KIT mutations, another 2 
harboured BRAF mutation and 8 had NRAS mutations. We found a higher frequency of 
mutations in tumours originating from the paranasal sinuses compared to tumours from 
the nasal cavity (p=0.027). 
 
 
In the fourth project we analysed 49 SNMM tumours for TERT promotor gene 
mutations, since former investigators found only a few driver mutations for these 
patients, who were never previously examined for this mutation. Recent studies of 
CMM have shown a high frequency (>70%) of driver mutations in this gene. 
TERT promoter mutations occur at a moderate frequency in SNMM. We suggest that 
SNMM tumours should be included in molecular characterization, since these 
alterations probably will be therapeutic targets in the near future.  
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1 INTRODUCTION 
Malignancies of the nasal cavity and the paranasal sinuses are rare, accounting for 
approximately 0.1% of all malignancies and 5% of all head and neck malignancies in 
Sweden(1). Moreover, the incidence is below one per 100 000 person years in Europe 
and in the USA(2, 3). These tumours usually present at an advanced stage, generally 
providing the patients poor prognosis(4). 
Sinonasal malignancies (SNMs) are a biologically heterogeneous group. Our 
knowledge of tumour biology continues to evolve, but will most likely improve with 
the development of new treatment strategies. The majority of SNMs have an epithelial 
histology, with squamous cell carcinomas (SCCs) the most common type(5). 
  
In the late 1960s and early 1970s, several reports described an association between 
SNM and occupational exposure to wood dust(6, 7). Further studies found an especially 
strong relationship between adenocarcinoma and exposure to dust from hardwood or 
leather(8, 9). Other important environmental factors associated with SNMs are tobacco 
and alcohol at least for squamous cell cancer(10, 11). Heavy air pollution was also 
suggested to be responsible for the increasing number of paranasal malignancies in 
Mexico City(12). 
 
In Sweden, the incidence of SNM has been reported to decrease since 1960(13). In 
agreement, Kuijpen and colleagues and Youlden and colleagues described similar 
findings in two recent reports of a large series of patients with SNM(2, 14).  
 
The first known descriptions of melanoma appeared in the manuscripts of Hippocrates 
in the 5th century, BC(15). In the 17th century, melanoma was described as a “fatal 
black tumour”, and in 1806, Professor R.Laennec used the term “melanosis”, to name 
this tumour entity before the Faculty of Medicine in Paris by  (Laennec was also 
inventor of the stethoscope). Robert Carswell first termed melanoma the designated 
word for these pigmented malignant tumours in 1838(15, 16). 
 
In 1869, A. Lücke was the first medical doctor to describe a patient with malignant 
melanoma of the nasal cavity(17). His reported depicted a melanotic sarcoma in the 
nasal mucous membrane of a 52-year-old man.  
 
The term melanoma originates from the malignant transformation of a cell type called 
the “melanocyte”. Melanocytes are neuroectodermally-derived cells whose precursors, 
the melanoblasts, migrate during the embryogenesis from the neural crest to their final 
destinations in multiple parts of the body where they differentiate to melanocytes. 
Melanocytes are melanin-producing cells. Melanin is the pigment responsible for 
colouration of the skin and other tissues and also protects the skin from ultraviolet (UV) 
radiation. Melanocytes are mainly present in the skin, specifically in the basal layer of 
the epidermis and within hair follicles. Melanocytes are also present in the eye, the 
mucosal membrane of the gastrointestinal, genitourinary and the respiratory regions 
and in the central nervous system´s leptomeninges. 
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Malignant melanomas emerge from melanocytes that are present in the skin as well as 
in other tissues, for example the nasal mucosa(18). As is well established, the major 
carcinogen in the genesis of cutaneous malignant melanoma (CMM) is through 
ultraviolet (UV) light(19). However, for mucosal malignant melanoma (MMM) the 
aetiology and predisposing factors are still unknown. 
 
The genetic background and phenotypic features of melanoma disease are 
heterogeneous. In recent years, the foundations of molecular classification have been 
established for CMM and several molecular genetic changes are now well 
described(20, 21). However, mucosal melanoma has not been characterized to the same 
extent in either molecular or genetic terms.  
 
A now well-established characterization of CMM is that its activation occurs via 
differing signalling pathways. The most important are the mitogen protein kinase 
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways. These pathways play a 
key role in the melanoma development by regulating cell survival and proliferation. 
Mutations of BRAF, NRAS and KIT oncogenes are the most common activation sources 
of these pathways in CMM(22-24). In contrast, mucosal melanomas do not have the 
same genetic background as cutaneous melanomas nor are they as well investigated as 
CMM.  
 
Even though primary SNMMs are most commonly localised at diagnosis, surgical 
resection is difficult(25), and the postoperative radiotherapy, used in Sweden has not 
improved survival time(26-28). Therefore the development of other more effective 
treatment options is essential for patients with these tumours. Recently, molecular 
targeted therapy has become available for malignant melanoma patients carrying 
defined driver mutations. For example, selective BRAF inhibitors, such as vemurafenib 
and dabrafenib, in phase III trials have demonstrated improvement in overall and 
progression free survival in CMM patients with BRAF mutations compared with 
standard systemic chemotherapy(29, 30). Targeted therapy also produced favourable 
results for patients with KIT mutated melanomas in phase II trials and case reports(22, 
31). Another phase II trial has demonstrated that treatment with MEK1/2 inhibitor may 
be beneficial for patients with NRAS mutated melanoma(32). These recent nonsurgical 
advances in the treatment of melanoma highlight the importance of investigating 
mutations in SNMM, which could serve as a possible target for drug therapy. 
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2 THE NASAL AND PARANASAL CAVITIES 
The nasal and paranasal cavities extend from the mucosa in the nose all the way to the 
choanae (the posterior nasal aperture). The paranasal sinuses are air-containing, paired 
spaces in the facial bone of the skull. The maxillary sinuses surround the nasal cavity; 
the frontal sinuses are located above and in front of the eyes; the ethmoidal sinuses are 
located between the eyes and sphenoidal sinuses are located behind the nasal cavity and 
ethmoidal sinuses. All the paranasal sinuses are named after the locations of the facial 
bones in the skull. The paranasal sinuses evolve by forming small air-containing spaces 
that are fully developed at about the age of 14 years.   
 
 
Figure 1 
1. Frontal sinuses 2. Ethmoidal sinuses 3. Sphenoidal sinuses 4. Maxillary sinuses 
(Source: Wikimedia commons – public domain) 
 
 
The nasal and paranasal cavities are covered by 160 cm2 mucosa that consists of 
respiratory and olfactory epithelium. Pigmentation of the oral mucosa is not 
uncommon; however benign pigmented lesions or melanosis of nasal and sinonasal 
cavities are extremely rare except for the olfactory mucosa, where paradoxically 
melanomas rarely occur(18). The majority of pigmented lesions in the sinonasal tract 
are melanomas(33).  
The respiratory epithelium is columnar-ciliated with goblet cells and a layer of mixed 
glands. The olfactory mucosa (totally 200-400 mm2), innervated by fibers of the 
olfactory nerve, covers the area of the olfactory cleft, the cribriform plate, and part of 
the superior turbinate. 
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The maxillary sinuses are the largest of all human sinuses, with an average size of 15 
cm3 each in adults. The superior wall of the maxillary sinus forms the floor of the orbit 
and the infraorbital nerve (one part of the trigeminal nerve (5th cranial nerve): sensory 
nerve innervating the upper lip, cheek, nose and lower eyelid) runs within it. This nerve 
is often affected in facial trauma or tumour growth of the maxillary sinus. 
The frontal sinus, which varies in size from 4-7 cm3, forms the bottom part of the 
anterior orbital roof, and the posterior wall of the frontal sinus forms part of the anterior 
cranial fossa. When a tumour develops in the frontal sinus, orbital or intracranial 
growth must be considered. 
 
The ethmoidal sinuses consist of six to ten air-containing cells of a total volume of 2-3 
cm3 on each side. In contrast to all the other sinuses the ethmoidal sinuses are fully 
formed at birth. The superior part of the ethmoid forms the anterior skull base and, 
laterally, the lamina papyracea; therefore, tumours evolving in the ethmoids have a 
pathway of spread intracranially and to the orbit. 
 
The sphenoid sinuses are the most posterior of the sinuses. They vary individually in 
shape and size, from about 0.5 to 3 cm3 on each side. The sphenoid sinuses start to 
develop after 6 years of age. Because, many vital structures such as the optic nerve, 
internal carotid artery and pituitary gland surround the sphenoid sinus, a tumour arising 
within may affect all these sites. 
 
 
           
Coronal   Sagittal   
     
Figure 2. Coronal and sagittal view of computed tomography of the sinuses. 
  
1=maxillary sinus, 2=ethmoidal sinus, 3=inferior turbinate, 4=medial turbinate, 5=nasal 
septum, 6=lamina papyracea, 7=skull base, 8=infraorbital nerve (N.V), 9=palate, 
10=frontal sinus, 11=sphenoidal sinus, 12=pituitary gland 
(Jangard 2014 with permission from patient)  
 
The lymphatic drainage architecture consists of an anterior system, which collects the 
lymph from the nasal pyramid and drains to the submandibular superficial cervical 
lymph nodes, and a posterior system that drains the nasopharynx and the posterior nasal 
cavity to the retropharyngeal lymph nodes and the jugular nodes. 
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3 EPIDEMIOLOGY 
Sinonasal malignancies consist of tumours evolving in the nasal cavity and paranasal 
sinuses, which include the maxillary, frontal, ethmoid and sphenoid sinuses. The 
epithelial tumours are the most frequent, and the majority of these tumours are SCCs 
followed by adenocarcinomas(5). Other tumour types of the sinonasal cavities are 
melanoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma (SNUC), 
esthesioneuroblastoma, sarcoma, lymphoma as well as metastases from other organs. 
Malignancies of the nasal cavity and the paranasal sinuses are uncommon and account 
only for approximately 5% of all head and neck malignancies and 0.1% of all 
malignancies in Sweden(1).  
 
The mean age at diagnosis varies among the malignant entities, although most SNMs 
are diagnosed in the sixth decade of life or later(2, 3, 14, 34). Patients with SNMMs 
have the highest average age at diagnosis of  >71 years; in contrast, adenoid cystic 
carcinomas are diagnosed at the lowest mean age at diagnosis: <62 years in Sweden. 
The overall incidence of sinonasal malignancies is between 5 and 9 per million for 
males and 2 and 5 per million for females(2). Other sites of head and neck cancer, such 
as laryngeal cancer, oropharyngeal cancer, salivary gland cancer and oral cancer, are to 
the contrary, much more common, i.e., the incidence varies from 10 to 50 per 
million(35). Interestingly, in a recent study of several Western countries the highest 
incidence rates of SNM were in Denmark, where the incidence rates were 7 per million 
for females and 12 per million for males(2). Many studies have shown that SNM is 
more common among males than females except for sinonasal melanoma and adenoid 
cystic cancer. The incidence of SNM is decreasing overall for men, yet the incidence 
for women has remained stable and even increased in some studies(2, 3, 13, 14). Even 
though the incidence of sinonasal cancer has remained constant or decreased somewhat 
in whites, considerable decreases were noted in other ethnic groups, particularly blacks. 
These differences likely reflect changing demographics and socioeconomic 
development(3). Another noteworthy shift is to more tumours originating in the nasal 
cavity compared to the paranasal sinuses, as reported in our study in Sweden (Paper I) 
as well as other studies(2). This shift in location has been described to give better 
prognosis for patients with SNM(34). 
As SNM does not have specific symptoms at initial presentation, the diagnosis is often 
mistaken and designated as for a benign disease such as nasal obstruction, nasal 
bleeding, tooth- and/or facial-pain. Other symptoms include cranial nerve involvement, 
tumour growth into the oral cavity, exophtalmus and loss of vision, facial swelling and 
lymph node metastasis to the neck and symptoms from distant metastasis.  
Generally, patients with these tumours have a poor prognosis, as the diagnosis has often 
been delayed until a locally advanced stage was reached.  Despite the different 
treatment strategies attempted, the 5-year survival rate is poor for patients with SNMs, 
especially for undifferentiated tumours and SNMMs. Owing to the scarcity of SNMs, 
treatment in Sweden as well as internationally has been based on local traditions. 
Therefore, the effect of such varied treatment modalities on the survival rate is still 
uncertain(3, 13, 36). 
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The incidence of CMM continues to rise worldwide, especially among Caucasian 
populations in the Western countries, and the annual increase of incidence is 3-7% (in 
Sweden over 5%)(37-40). In Sweden, CMM is the sixth most common tumour type and 
its incidence is increasing faster than that of any other malignancy(1). About 3300 new 
cases are diagnosed each year. The increased incidence of CMM might stem from such 
diverse factors such as changes in sun exposure, public awareness, skin screening 
programs and increased ability to diagnose thin melanomas(37). 
 
 
New CMM cases and mortality per 100 000 per year in Sweden 
 
 
 
Figure 3. Age standardized (2000) incidence in Sweden. Green=incidence men; 
Purple=incidence women; Dotted green=mortality men; Dotted purple=mortality 
women. (Cancer Incidence Sweden, 2012) 
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In Europe, the highest incidence of melanoma are in Sweden, Norway, Denmark, 
Ireland, The Netherlands, Switzerland and Slovenia, see figure 4. 
 
 
 
 
Figure 4. Age-standardized incidence of CMM in Europe. (Globocan 2008 (IARC)) 
 
In Europe, the highest incidence rates of melanoma are reported in the Northern 
countries; Denmark, Norway and Sweden has the highest incidence compared to 
Iceland and Finland, which have much lower incidence(38). The highest incidence rates 
of all occur in New Zealand and in Australia because of the greater exposure to UV 
radiation and the fact that much of the population has ancestors from Europe(41). 
Accordingly, light-skinned humans have a much higher incidence of melanoma than 
those with dark skin or of Asian origin(37, 42, 43).  In the USA the lifetime risk of 
developing melanoma in Caucasians is 1 in 50, compared to the much lower incidence 
in African-Americans, 1 in 1000(44). 
 
The average age at diagnosis of CMM in Sweden is 60 years for women and 64 years 
for men, whereas SNMM is diagnosed at a much later age. The 5-year survival rate for 
CMM in Sweden is 92% for women and 86% for men(45). However, for mucosal 
melanoma, incidence studies are rare and, for the most part, too few patients are 
included to draw any firm conclusions on the incidence rate.  
 
The mucosal melanoma incidence for ano-rectal and vulvar melanomas, showed an 
inconsistent pattern with generally decreasing (46) or stable (47, 48) rates. In only one 
study did numbers for MMMs of the ano-rectal region tend to increase, especially for 
men(49). According to other recent studies, MMMs do not generally seem to be 
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increasing. In Sweden, MMMs account for about 2% of all melanomas(50) and the 
most common primary site, among MMMs registered in the National Cancer Registry 
from 1960 to 2009, was the vulva (35.6%), followed by the ano-rectal region (25.8%), 
and sinonasal cavities (SNMM) (19.7%).  
 
Table 1 
 
Cutaneous and Mucosal Melanoma in Sweden 1960-2009  
(The Swedish National Cancer Registry) 
 
 
Uveal melanoma (3717) excluded 
 
 
 
Of all the malignancies of the nasal and paranasal region, 1-12% consist of SNMM (13, 
36, 51). Differing incidences have been reported for MMM among distinct ethnic 
groups, as well as for CMM, see above. For example, oral mucosal melanomas account 
for 7.5% of all melanomas among the Japanese population versus less than 1% for 
Caucasians(52, 53).  
 
The prognosis is generally poor for patients with MMM considering that the 5-year 
survival rate has been reported as 25%(42). However, the numbers differ among sub-
sites and the 5-year survival rate in Sweden for primary ano-rectal melanomas is only 
18% and 35% for vulvar melanoma(46, 48). For SNMM, the 5-year survival rate varies 
from 20-28%(26, 54, 55), but has improved during the period from 1960-2000 in 
Sweden(55). 
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4 MELANOMA RISK FACTORS 
Several studies have described an association between sinonasal malignancies and 
occupational exposure to wood dust(6, 7). Exposure to leather dust and wood dust is 
also known to be strongly related to the development of adenocarcinoma in the 
paranasal sinuses(8, 9). Other aetiologic possibilities including inhaled carcinogens 
(e.g. from smoking, formaldehyde, paints and lacquer) on the development of SNM 
could not be excluded. Additionally, high levels of air pollution have been described as 
a causative factor for SNM in general(9, 12). Tobacco and alcohol, at least for SCC, are 
also associated with SNMs(10, 11). Overall, the decreasing incidence of most 
histological types of SNM may be attributed to better working conditions and reduced 
air pollution over the years. 
 
For SNMM the risk factors are mainly unknown, although those linked with the 
development of CMM are well established. UV radiation from either the sun or from 
indoor tanning devices is believed to initiate the tumour formation of CMM by 
damaging DNA and creating mutations in tumour suppressor genes and proto-
oncogenes(56-58). The pattern of repeated sun light exposure is believed to play a 
crucial role in melanoma genesis, since intense and even intermittent exposure to UV 
radiation produces a high risk of melanoma development in humans(59). Moreover, 
individuals with a family or personal history of melanoma are at a greater risk of 
developing CMM(60). However, the heredity factors for SNMM are not known and 
have not yet been investigated. 
 
We know that the nasal septum and the turbinates are the most frequently affected 
subsites where SNMM arises(55). That observation suggests that inhaled carcinogens 
could be responsible, since most inhaled air passes through the nasal cavity, during 
normal breathing. Medicine and carcinogens can be filtered by and conjugated to 
melanins, and also metabolized by melanocytes, which may induce carcinogenesis(61, 
62). Occupational exposure for formaldehyde may also be a potential cause of SNMM, 
as is reported in a publication by Holmström et al(63). 
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5 DIAGNOSIS 
 
The symptoms of the SNMM and SNM patients at their first visit to the clinician are 
heterogeneous and often nonspecific but usually referable to the tumour site. Moreover, 
the expansion of a SNM in the space of a large air-containing paranasal sinus allows 
tumour growth that is virtually asymptomatic. This explains why SNM often remains 
undiagnosed until an advanced stage of disease, when the patients still have only minor 
symptoms. In fact, some of the initial symptoms are difficult to distinguish from such 
common nasal complaints as congestion and epistaxis. Therefore, with symptoms that 
may be imprecise, these patients delay seeking medical care. Patients who actually had 
SNMM, but presented with epistaxis had a significantly better prognosis than those 
with only nasal congestion(55), probably because patients found epistaxis more 
alarming than nasal congestion and therefore looked for medical examination sooner.  
 
These tumours can also present as a unilateral polyposis. Such lesions are easily 
mistaken for a benign disease, which clinicians should keep in mind to avoid a harmful 
“doctor´s delay”. The most common symptom at diagnosis of SNM is facial swelling 
followed by nasal blockage and epistaxis(64) however for SNMM the most common 
symptom is epistaxis followed by nasal obstruction(55). 
 
At diagnosis, patients with SNM rarely have cervical lymph node metastasis or distant 
metastasis; however the majority of the SNMs present at a clinical locally advanced 
stage(64, 65). For SNMM, the tumours tended to become evident at a more advanced 
stage over the years 1960 through 2000 in Sweden(55). Possibly, today’s increasingly 
sophisticated techniques, including CT scanning, MRI, and PET/CT scanning, could 
account for the heightened number of more advanced tumours recently recorded.  
 
The histopathology for SNM, especially SNMM, is challenging. As many as 20% or 
more SNMMs are initially misdiagnosed (e.g. as poorly differentiated squamous cell 
carcinoma, olfactory neuroblastoma, lymphoma, or sarcoma)(55). The diagnosis of 
melanoma is complicated. Not only do the several histological types of melanoma vary 
considerably, another difficult issue is that the melanin content ranges from large to 
small amounts of pigment. Lesions without pigment (amelanotic) in the sinonasal 
cavities may be diagnosed as other sinonasal malignacies(66-68). Fortunately, the 
histological diagnostics have improved over the years, thereby reducing the number of 
misdiagnosed patients. In analogy with the methods used for CMMs, the application of 
immunohistochemical stains, such as S-100, HMB-45 and Melan-A, can improve the 
diagnosis of these tumours(69). Histologically, most SNMM have an epithelioid or 
spindle cell like (sarcomatoid) growth pattern(66, 68), but considerable controversy 
remains in that individual studies report different results.  
 
The most common site of SNM is the nasal cavity, especially for SCC and SNMM(1). 
An increasing proportion of tumours originating from the nasal cavity compared to the 
maxillary sinuses for all SNM over the study period was also found in a recent article 
by Youlden and colleagues(2). The reason for this is unknown. Perhaps the patients’ 
and doctors’ delayed recognition of tumour types in the 1960s resulted in the former 
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misclassifications compared to greater accuracy of the 2010s, when better diagnostic 
tools and earlier diagnoses provided more reliable information as to the origins and 
precise locations of theses tumours.   
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6 SINONASAL MALIGNANCY CLASSIFICATION 
Epithelial tumours are the most common histology of SNM. Of the epithelial tumour 
types, the SCC predominates followed by adenocarcinomas. Melanoma is the most 
common non-epithelial pathology in Sweden. The most common types of SNM in 
Sweden from 2000-2010 were SCCs, followed by melanoma, adenocarcinoma, adenoid 
cystic cancer and undifferentiated cancer. Interestingly, there has been a significant 
shift in distribution of different histologic types from 1960 to 2010, see Table 2. 
 
Table 2  
Sinonasal malignancies in Sweden 
 
 
 
The differences in distribution over time of the various histological types might reflect 
an actual increase and decrease of different histological types but also improved 
diagnostic methods.  
SCC, the most common type of SNM, is more common in men than women (63 % men 
in Sweden)(1) and appears to be related to alcohol and tobacco use as well as inhaled 
carcinogens(10, 11). However alcohol and tobacco use as a risk factor is controversial, 
since other studies failed to show their association to SNM(70). A strong association 
between SCC and nickel exposure was also reported for workers at a nickel refinery in 
Norway(71). In Sweden, the most common localization for SNM is the nasal cavity, 
but many other reports refer to the maxillary sinus as the most common site of 
origin(65, 72). The majority of the patients with sinonasal SCC presents with a locally 
advanced disease (T3-T4)(65, 73). At presentation about 2-5% have nodal involvement 
and nodal metastasis at diagnosis is associated with poor prognosis(65, 72).  
Adenocarcinoma has a strong relationship with occupational exposure to leather and 
wood dust, which probably explains the male predominance (76% in Sweden) and also 
the decreasing incidence as the working conditions improve over time. Lymph node 
engagement at diagnosis is lower than for SCC(65, 72).  
Adenoid cystic carcinoma, which has a slight female predominance (53%), most 
commonly presents in the maxillary sinus(1, 74, 75). Diagnosis is often delayed as the 
tumours progress slowly and have a long clinical course during which the symptoms 
often mimic those of chronic rhinosinusitis and tend to include perineural extension(75, 
76). Regional and distant metastases at diagnosis are rare(75, 77). The long-term 
survival is poor as the tumour spread (perineural spread) is often undetected and 
misjudged on radiologic scans(74).  
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7 CLASSIFICATION OF MELANOMA 
 
7.1 CUTANEOUS MALIGNANT MELANOMA 
For more than 40 years, CMM has been classified into multiple subtypes based on the 
tumour’s anatomic location and growth pattern of the melanoma cells. The four main 
subtypes are superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo 
maligna melanoma (LMM) and acral lentiginous melanoma (ALM)(78). Over the 
years, other subtypes have been added such as spitzoid melanomas, nevoid melanomas, 
desmoplastic melanomas and others that are rare. The non-cutaneous melanoma 
subtypes consists of ocular and mucosal melanomas (Table 1).  
 
7.1.1 Superficial spreading melanoma 
SSM is the most common subtype accounting for about 81-84% of all melanomas in 
patients younger than 50 years and 60-63% in patients over 50 years. SSM is, in fact, 
the subtype that increases most of all melanomas(45). The growth pattern of SSMs is 
characterized by lateral spreading of melanoma cells within the epidermis, known as a 
pagetoid pattern. This subtype has the strongest correlation to areas with intermittent 
sun-exposure, such as the trunk in males and the extremities (mainly lower limbs) in 
females, and is also associated with the presence of pre-existing nevi(79). Notably, 
SSM is characterized by a high frequency of BRAF mutations(80). 
 
7.1.2 Nodular melanoma 
NM is the second (about 10-15%) most common subtype of CMM, is the most 
aggressive and is diagnosed mainly in patients older than those with SSM. Instead of 
arising from pre-existing nevi as for SSM, NM may appear in a spot where no lesion 
previously existed. The growth pattern is characterized by an invasion of the dermis, 
vertical growth phase, and lacking the radial growth phase. The BRAF mutation 
frequency is significantly lower in NM than for SSM; however, the NRAS mutation is 
more frequent in NM(80, 81).  
  
7.1.3 Lentigo maligna melanoma 
About 4-15% of all CMM is represented by LMM and is diagnosed most commonly on 
chronically sun-damaged skin. Most of this skin tumour class originates in the head and 
neck region. Patients younger than 40 years are rarely diagnosed with LMM(82-84).  
Histologically, LMM cells proliferate along the basal layers of the skin(85). 
 
7.1.4 Acral lentiginous melanoma 
ALM is the least common subtype of CMM accounting for 1-10% of all 
melanomas(42, 86). It occurs predominantly in distal sun-protected parts of the body, 
such as the palms, soles and nail beds. ALM is most frequently diagnosed in elderly 
people and their prognosis is poor compared to persons with other subtypes, partly 
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depending on delayed diagnosis(87). Histologically, there are no exact criteria that are 
necessary for the diagnosis of ALM, causing considerable difficulty, when attempting 
to determine the diagnosis(86). 
ALM patients sometimes harbours KIT mutations, but BRAF and NRAS mutations are 
relatively rarely found among these patients(88). 
 
7.2 NON-CUTANEOUS MELANOMA 
Relative to melanoma of the skin, non-cutaneous melanomas are rare and represents 
about 8% of all melanomas in Sweden(1). Ocular (most common) and mucosal 
melanomas represent the majority of the non-cutaneous melanomas. The frequency of 
of non-cutaneous melanomas is higher among Caucasians compared to blacks, which is 
consistent with CMM(89). Most of the patients are elderly, and the prognosis is dismal 
compared to those with CMM. Owing to the tumour’s rarity and the limited amount of 
relevant studies, information about the pathogenesis, risk factors and predisposing 
factors for non-cutaneous melanomas is still to a large extent lacking.  
 
7.2.1 Ocular melanoma 
Ocular melanoma is the most common type of non-cutaneous melanoma in Sweden, 
accounting for about 100 new cases every year(1). Most of these melanomas arise in 
the uveal tract, e.g. the choroid, ciliary body and iris. More than 80 % of ocular 
melanomas harbour activating somatic mutations in GNAQ or the GNA11 oncogenes, 
which can lead to activation of the MAPK pathway(90, 91). 
 
7.2.2 Mucosal melanoma 
Less than 2% of all types of melanomas consist of primary malignant mucosal 
melanoma (MMM)(1, 42, 89). The most common primary site of MMMs in Sweden 
from 1960 to 2009 is the vulva, followed by the ano-rectal region, and sinonasal 
cavities (SNMM), see Table 1. Other primary sites included the vagina, oral cavity, 
penis and urethra, in that order. SNMM is the most common type of mucosal 
melanoma in the head and neck region(1, 92). The diagnosis of MMM usually occurs at 
an advanced stage and affects primarily the elderly. Their prognosis is poor with a 5-
year survival of about 25%(69). UV-radiation and genetic risk factors such as family 
history of melanomas and high frequencies of melancytic nevus do not seem to be 
associated with mucosal melanoma. Histologically, MMM is classified as SSM, NM, 
and mucosal lentiginous melanoma (MLM). ALM and MLM are histologically very 
similar and sometimes identical, however ALM is not present in the in MMM(93, 94). 
In vulva melanoma, MLM is the predominating melanoma subtype(95). However, the 
histological classification of SNMM has not yet been investigated to my knowledge.  
The genetic background differs from CMM, whereas MMM is characterized by a 
higher frequency of KIT mutations and/or amplifications and a lower frequency of 
BRAF mutations(88, 96).  A recent study of MMM revealed that KIT mutations in 
vulvar melanomas had a significantly higher frequency compared with tumours at other 
sites (35% vs 10%). This outcome implies that the KIT mutation rate in MMMs differs 
depending on anatomical sites(23).  
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8 STAGING SYSTEM FOR SNMM 
 
Ballantyne established a staging system for CMM and MMM of the head and neck in 
1970(97), which is still widely used. This system consists of stage I for local disease, 
stage II for regional disease, and stage III for distant disease. The prognostic assessment 
of this system has been a controversial, because the majority of the MMMs seem to fall 
into the Stage I category(98, 99). Moreover, Breslow thickness is often difficult to 
distinguish, because the SNMM tumours are commonly resected in pieces, and the 
Clark level is not applicable, because the mucosa and skin differ anatomically(100). As 
a result of this problem, Prasad and colleagues has proposed a micro-staging system 
according to an invasion into three tissue compartments(100), and Thompson and 
colleagues have described another staging system being histology- and site-
specific(68). However, these improvements have unfortunately not resulted in using the 
new staging systems in the medical literature. The International Union Against Cancer 
(UICC 7th edition) has now established the TNM staging for melanoma in the upper 
aerodigestive tract and this system maybe more effective in classifying these highly 
malignant tumours(101). According to the 7th UICC, T1 and T2 as well as stage I and II 
are omitted when mucosal melanomas are considered to be aggressive tumours. Stage 
III (T3) is designated when a tumour is limited to the mucosa; stage IVa (T4a) applies 
when the tumour invades the deep soft tissue, cartilage, bone or overlying skin without 
lymph node involvement (N0) or T3 with lymph node involvement (N+), and stage IVb 
(T4b) depicts a tumour that invades the brain, skull base, cranial nerves or carotid 
artery with or without lymph node involvement.  Stage IVc (any T, any N) is for 
melanomas with distant metastasis (M+). N indicates regional lymph nodes, and M 
indicates distant metastasis.  
 
To form a comprehensive staging system, the prognostic factors involved in SNMM 
must be more thoroughly investigated and understood. However, for all the other types 
of SNM the 7th UICC system is used to classify tumours worldwide and does not, to the 
same extent, entail the same classification issues as those for SNMM. 
 
 
 
  16 
9 TREATMENT 
Although most of the SNMs are localised at diagnosis, the close distance of the brain 
and cranial nerves as well as the eye contributes to the difficulty of radical surgery and 
radiotherapy. Furthermore, these treatments, themselves, are associated with serious 
complications (25, 102).  
 
Because of the rarity and the various biological behaviours of SNM, there is no 
consensus regarding treatment for these patients. Surgery alone, pre- or post-operative 
radiotherapy or radiotherapy alone are the foundation for treating these 
malignancies(65, 103, 104). Depending on the stage and histologic state of disease, 
some patients might benefit from adjuvant chemotherapy, e.g. individuals with 
sinonasal undifferentiated carcinoma (SNUC) and sarcoma.  
 
Nearly 200 years ago the first resections of the maxilla were described(65, 105); 
however, since then, the surgical treatment for SNM has remained the same. Not until 
the endoscopic techniques were introduced for the surgical treatment of malignant 
tumours have new option arisen. Now we know that in selected patients, endoscopic 
surgery of SNM has an identical outcome as open surgery with, at the same time, a 
significantly lower rate of complications(26, 106). 
 
Over the years, more sophisticated imaging techniques (e.g., magnetic resonance 
imaging (MRI), positron emission tomography (PET) and image guide surgery) have 
improved both pre- and post-operative illustrations of the tumours, thereby 
ameliorating the rate of tumour resection and improving the precision of radiotherapy. 
Presently, the main cause of treatment failure is local recurrence rather than distant 
disease for both SNM and SNMM(2, 55, 107).  
 
Primary surgery followed by postoperative radiotherapy is the main standard for 
treatment of patients with SNMM in Sweden and in many other countries. Some 
studies indicate that postoperative radiotherapy increases the rate of locoregional 
control; unfortunately, though, the survival time has not been reported to improve(26-
28). However, other studies emphasize the advantages of adjuvant radiotherapy for 
SNMM(108, 109). In contrast, some reports state that patients treated with adjuvant 
radiotherapy have a worse prognosis than those without radiotherapy. This is an 
obvious selection bias, of course, as non-radical or inoperable tumours are more likely 
to be treated with radiotherapy(99).  
 
The well-known activating mutations in BRAF-, and KIT-genes in CMM now enable 
targeted therapy. Until now, this treatment has been an option mainly for CMM. Recent 
studies have shown that selective BRAF inhibitors (vemurafenib and dabrafenob) 
improve both progression-free and overall survival compared to the standard systemic 
chemotherapy(29, 30). For patients with KIT mutated melanomas, case reports and 
phase II trials have indicated promising effects of targeted therapy with imatinib and 
dasatinib(22, 31). Another phase II trial demonstrated that patients with NRAS mutated 
melanomas might benefit from treatment with MEK1/2 inhibitor(32). These new 
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therapeutic advances stress the importance of identifying mutations of these oncogenes 
in patients with SNMM.  
 
Another major advance in recent years in the treatment of metastatic melanoma 
(including metastatic mucosal melanoma) is to target the immune system instead of the 
tumour. Ipilimumab, a monoclonal antibody, regulates the immune system by 
inhibiting cytotoxic T-lymphocyte-associated-antigen-4 (CTLA-4). This antibody is a 
negative regulator of T-cell activation that stimulates T-cell proliferation and 
infiltration thereby inducing tumour cell death. The result is improved overall survival 
time as well as long-term survival for patients with advanced metastatic 
melanoma(110-112).  
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10 PROGNOSIS 
The prognosis for patients with SNM differs depending on the particular histological 
type each individual manifests. As SNM is a very rare disease, drawing indisputable 
conclusions about the prognostic factors and different treatment outcomes is difficult. 
As far as I know, there has been no randomized clinical trial of various treatments for 
SNM patients, and the possibility of accomplishing such a study is most unlikely.  
 
Women diagnosed with SNM tend to have a better prognosis than men in Sweden. But 
for individuals with this tumour, regardless of its histological type, the 5-year survival 
time has improved over time from 1960–2010. Those with adenoid cystic cancer have 
the best chance of 5-year survival followed by patients with adenocarcinoma and SCC, 
whereas sufferers of SNUC and SNMM have the poorest prognosis. Patients with 
tumours arising from the nasal cavity have a significantly better prognosis than those 
with tumours originating from the paranasal sinuses(3, 36, 51).    
 
The prognosis is generally poor when the tumour is SNMM, i.e., a 5-year survival rate 
of 20-28% (26, 54, 55), but has improved during 1960-2000 in Sweden(55). Women 
have a significantly better survival statistics than men. Moreover, patients with ano-
rectal melanomas have the same gender-associated survival difference in Sweden(48), 
as also found for CMM in Sweden (113) and in other countries(42). Additionally, 
multifactorial analyses have shown that gender is an independent prognostic factor for 
CMM(114).  
 
Tumours originating from the nasal cavity provide a better prognosis compared to 
tumours originating in the maxillary sinuses, in the ethmoid sinuses or overlapping 
sinonasal regions(28). The lesions in the nasal cavity cause earlier symptoms and are 
easier to visualize and detect, which offers an opportunity for earlier diagnosis and, 
therefore, improves treatment outcome. The well provided lymphatic and vascular 
systems of the submucosa ameliorate development of mucosal melanoma metastasis. 
Most commonly, MMMs relapses in their local environment, and unfortunately, this 
recurrence often serves as a marker of distant disease(99).  
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11 SIGNALLING PATHWAYS IN MELANOMA 
Numerous regulatory pathways have been implicated in the melanoma development. 
Recent whole-genome analysis of melanomas has identified a higher mutation load in 
melanoma tumours compared with most other types of malignancies(115). Only a small 
number of these mutations, though, are thought to be involved in melanoma 
development.  
 
The most important pathways in the initiation and progression of cutaneous melanomas 
are those known as RAS-RAF-MEK-ERK, or MAPK pathway, and the 
phosphatidylinositol 3-kinase (PI3K)-Akt-pathway. These pathways are activated in 
melanomas commonly through mutations in the BRAF, NRAS and KIT oncogenes(23, 
24). Mucosal melanomas seem to have a different genetic background that 
differentiates them from cutaneous melanomas. The frequency of BRAF mutations are 
higher with respect to melanomas evolving in the trunk and skin without chronic sun 
damage compared to mucosal melanomas(80, 116, 117), whereas NRAS mutations are 
more frequent in melanomas arising in extremities and skin with chronic sun 
damage(80, 117). Former studies have shown that some mucosal melanomas harbour 
mutations and/or amplifications of the KIT gene, but very rarely contain BRAF 
mutations(88, 96). 
 
 
11.1 MITOGEN ACTIVATED PROTEIN KINASE PATHWAY 
MAPK pathway is a signalling pathway that becomes activated through extracellular 
growth factors, cytokines and hormones. This pathway regulates many different 
cellular functions including proliferation, survival, differentiation, growth and 
motility(118, 119). In many tumour cells, the MAPK pathway is hyper-activated as a 
result of different mutations involving the components of this pathway. The MAPK 
pathway consists of a multiple components as represented in figure 5. 
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Figure 5. The MAPK pathway. three RAS (HRAS, KRAS and NRAS), three RAF 
(ARAF, BRAF, CRAF), two MEK (MEK1 and MEK2) and two ERK (ERK1 and ERK 
2) proteins.  (Zebary, 2013) 
 
 
11.1.1 RAS 
The RAS (rat sarcoma) protein is a GTPase located in the inner surface of the cell 
membrane. It transduces growth signals from the extracellular surface to downstream 
effectors. There are three isoforms of the RAS gene, HRAS, NRAS and KRAS that are 
commonly mutated in human cancers. Of these isoforms the NRAS gene is most 
frequently mutated in melanoma development (17% - 29% in primary CMM)(120-122) 
resulting in constitutionally activated RAS protein independent of the receptor tyrosine 
kinase (RTK e.g., KIT, PDGFR, EGFR) stimulation. This eventually stimulates cell 
proliferation and inhibits apoptosis by activating both MAPK and PI3K pathways.  
In CMM, NRAS mutations are associated with older age at diagnosis, nodular type, 
high Breslow thickness as well as chronic sun-exposed areas and the extremities(80, 
117, 122).  
 
  21 
11.1.2 RAF 
The three RAF (rapidly accelerated fibrosarcoma) genes are located on separate 
chromosomes and encodes for three serine/threonine kinases (ARAF, BRAF and 
CRAF). The BRAF mutations are relatively common in CMM (41% - 59%)(80, 122, 
123) and are most frequently found in younger patients, in SSM-type, thin melanomas, 
intermittently sun-exposed areas and the trunk(80, 117, 122).  
 
 
11.2 PHOSPHATIDYLINOSITOL 3-KINASE-AKT PATHWAY 
The PI3K-Akt pathway is a well-known regulator of cell survival in melanoma and 
other cancers(124). See the pathway, including KIT receptor structure, presented in 
figure 6. 
PI3Ks (three different classes) are lipid kinases that trigger the activation of Akt 
through phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-bisphosphate (PIP3), which in turn enables phosphorylation 
and activation of Akt. The PI3K-Akt pathway is activated in human cancers usually 
through mutation of receptor tyrosine kinases (RTK) for example KIT, upstream 
effectors (e.g. NRAS), inactivation of inhibitors (e.g. PTEN) or alteration in Akt and 
PIK3CA genes (coding for the catalytic subunit of PI3K)(125). 
 
11.2.1 KIT 
KIT is a protein encoded by the KIT gene, also known as c-KIT or CD117. The KIT 
receptor protein is a transmembrane RTK that is expressed on the surface of 
melanocytes and several other cell types. It consists of three domains: extracellular, 
transmembrane and intracellular (Figure 6). When KIT is activated extracellularly by 
stem cell factor (SCF, also known as c-kit ligand or steel factor), the intracellular 
domain phosphorylates and activates signal transduction of many downstream effectors 
such as MAPK and PI3K-Akt pathways(119). 
 
The KIT receptor signalling is crucial for melanocyte development, proliferation and 
survival and is also important in melanoma pathogenesis(31). The KIT mutations is 
relatively common in CMM on chronically sun-damaged skin, in acral melanoma and 
in mucosal melanoma, whereas it is very rare in melanomas on skin without chronic 
sun-damage or in conjunctival melanoma(88, 96). In a recent investigation by Omholt 
and colleagues of various mucosal melanomas, it was reported a higher frequency of 
KIT mutations in vulvar melanomas in relation to other mucosal melanomas located 
elsewhere. They concluded that the frequency of KIT mutations in MMM varies with 
anatomical site(23). Although a recent Chinese report showed that KIT mutations 
adversely affected survival(126), we did not find any correlation between KIT mutation 
in SNMM patients and survival(127).  
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Figure 6. The KIT receptor structure and the PI3K-Akt pathway (Zebary 2013). 
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12 TELOMERASE REVERSE TRANSCRIPTASE 
PROMOTER 
 
In 1985, Elizabeth Blackburn and Carol Greider were the first to discover telomeres. 
Telomeres are structures localized at the ends of the human chromosomes and are 
required for chromosomal protection(128, 129). With each cell division in normal cells, 
the telomeres are shortened. When they reach a critical length, DNA-damage responses 
are activated, which leads to senescence and apoptosis. However, cancer cells with 
chromosomal aberrations activate telomerase and prevent the shortening of telomeres 
despite the DNA-damage signal, which leads to uncontrolled growth and proliferation 
(Figure 7)(130, 131). 
 
The telomerase reverse transcriptase gene (TERT) is located on the short arm of human 
chromosome 5. The core promoter spans 330 bp upstream of the translational start 
site(132, 133). Telomerase activity is important in the development of senescence and 
in obtaining unlimited growth potential in cancer cells. The activation of telomerase 
through TERT promoter mutations is thought to be an early event in developing 
cancer(133-135). Other potentially carcinogenic biological effects of telomerase protein 
include inhibition of apoptosis, enhanced cell proliferation and DNA damage response 
regulation(136), see figure 7. As is well established, telomerase plays an important role 
in tumourigenesis; on the other hand, the dysregulation in cancer cells is still not 
entirely understood, especially not for melanoma. The TERT promoter mutations have 
been reported to create E-twenty-six(ETS)/ternary complex factor (TCF) transcription 
binding sites. ETS transcription factors may become activated through impaired 
regulation of MAPK signalling. Therefore, some have hypothesized that TERT 
promoter mutations might increase gene expression(137). 
 
The increased expression of telomerase, when for example TERT promoter mutations 
are present, may be useful as a target for therapy. Several strategies of therapeutic 
telomerase inhibition in numerous cancers that are now the subjects of clinical trials, 
including small molecular inhibitors (enzyme inhibition), antisense oligonucleotides 
(targeting RNA template of telomerase), immunotherapy (using TERT peptides to elicit 
immune responses), gene therapy (TERT promoter driven tumour cell lysis), and 
telomere- and telomerase-associated proteins (disrupting the telomerase assembly 
resulting in non-functional telomerase), G-quadruplex stabilizers (blocking telomerase 
access to telomeres) and a T-oligo approach (blocking of telomerase to induce DNA 
damage)(138). 
 
Screening for promoter mutations represents a new way of finding significant 
alterations when mutations are missing in the coding sequences(137, 139, 140). 
Huang and colleagues recently reported a high prevalence of TERT promoter mutations 
in CMMs(137). Horn and colleagues also demonstrated a germline TERT promoter 
mutation in a kindred with familial CMM(139). Additionally, Egberts and colleagues 
have now found a low frequency of TERT promoter mutations in mucosal melanomas, 
but the frequency in SNMM was not specifically reported(133). 
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Figure 7. TERT in tumorigenesis (Ryott 2014). 
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13 AIMS OF THESIS 
 
The overall aims of this thesis are to establish population-based trends for SNMM and 
SNM in Sweden and to contribute to the molecular characterization of SNMM by 
investigating the most commonly mutated oncogenes (BRAF, NRAS and KIT) in 
melanoma as well as to determining the TERT promoter mutation frequencies in 
SNMM. 
 
 
Specific aims: 
 
Paper I:  The aim was to evaluate the incidence trends, survival rates and clinical 
features for all patients diagnosed with SNM in Sweden from 1960-2010. 
 
 
Paper II:  In this study our aim was to investigate incidence trends, prognosis, 
tumour specific survival as well as clinical features for all patients 
diagnosed with primary SNMM in Sweden from 1960-2000. 
 
 
Paper III:  The purpose of this study was to determine the frequency of mutations in 
the BRAF, NRAS and KIT oncogenes in SNMM and to investigate the 
association between mutations and clinical and histological 
characteristics. 
 
 
Paper IV:  The intent was to establish the TERT promoter mutation frequencies in 
SNMM and to correlate associations between mutations and clinical 
characteristics. 
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14 MATERIALS AND METHODS 
14.1 PAPER I 
14.1.1 Subjects 
All patients in Sweden diagnosed with sinonasal malignancies from 1960-2010 were 
identified using the Swedish Cancer Registry (SCR). The SCR covers approximately 
96% of all cancer cases diagnosed in Sweden. Since the reliability of the SCR was 
uncertain during the first two years, we used data from 1960(141, 142).  
 
We included all malignant tumours in the sinonasal area, numbered 160.0, 160.2, 
160.7-160.9 according to the ICD-7.  Information obtained from the SCR included 
histological subtype, localization, patient’s age and date at diagnosis and gender. 
Unfortunately, information on clinical stage is only available in the SCR for patients 
diagnosed from 2004 onward and could not be used to study long-term temporal trends.  
 
Using the emigration-, immigration- and date of death registers from Statistics Sweden 
we were able to identify patients lost to follow-up and to analyse survival. For the 
survival analysis we included patients diagnosed up to 2010 with follow up to the end 
of 2012. 
To calculate incidence rates, annual population- and gender distribution data were also 
retrieved from Statistics Sweden (Statistical Yearbook of Sweden). 
 
14.1.2 Statistical analysis 
The cancer patients were divided into 16 groups according to age at diagnosis, with a 
range of five-years. We divided the calendar period into five-year-periods. Incidence 
rates were calculated by dividing the number of cases in each calendar period by the 
total average population in each age group in respective calendar period. The rates were 
adjusted to the Swedish Standard Population of year 2000 as well as the World 
Standard Population of 1966.  
 
We estimated relative survival ratios, where relative survival provides a measure of 
excess mortality as a result of cancer without relying on cause of death information 
(143). The definition is the observed all-cause survival in the patients divided by the 
expected survival of an equal group in the general population. We used the Ederer II 
method from Swedish population life-tables stratified by age, sex, and calendar period 
to estimate expected survival(144). We also used Poisson regression to adjust the effect 
of age at diagnosis, sex, and calendar year at diagnosis, on the excess mortality rate 
ratio. To estimate the age-standardized relative survival, we used age distribution (<55, 
55-69, ≥70) at malignant diagnosis among all patients (145).  
 
Statistical analysis was done in STATA, SAS 9.2 and Excel. 
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14.2 PAPER II 
14.2.1 Subjects 
We identified all the patients from 1960 - 2000 using the SCR and included patients 
according to the ICD-7 codes numbered 160.0, 160.2, 160.7, 160.8 and 160.9, and only 
patients with a specific histopathologic code of malignant melanoma were included. 
We analysed all patients for concomitant primary CMMs, which might indicate 
metastatic disease and no one was found. Clinical records and pathology reports were 
collected throughout Sweden, except for 11 patients whose medical records were not 
retrievable. Three patients were excluded due to incorrect diagnosis. Two patients were 
included, where the initial diagnosis mistakenly was coded as malignant melanoma of 
the palate and the nasopharynx. The medical charts revealed that those tumours 
originated in the nasal cavity. Altogether 186 SNMM cases were included. Before 
1980, histology examination of melanoma tumours was commonly supplemented with 
the Masson silver staining to confirm presence of melanin pigment. After the 1980s 
immune markers like HMB45 and S-100 were used to verify the melanoma diagnosis. 
The histology sections were reviewed in 90 of the 186 cases. Information on standard 
demographic data such as age at diagnosis, gender, patient’s residence, treating 
hospital, date of diagnosis as well as overall survival time were obtained from the SCR. 
We extracted diagnoses, symptoms, TNM (T=primary tumour size and nearby tumour 
invasion; N=regional lymph nodes; M=distant metastasis) classification and Stage, 
disease site, mode of treatment, five-year local control, and tumour-specific survival 
rate from the clinical records. We used the classification from the seventh edition of the 
TNM Classification of Malignant tumours from UICC (International Union Against 
Cancer) (2009) when comparing the outcome of the disease. Staging was done 
according to Ballantyne´s clinical system(97).  
 
14.2.2 Statistical analysis 
We divided the SNMM patients into eight groups according to age at diagnosis, each 
spanning ten years, except for the youngest (0 - 24 years) and oldest (≥ 85 years). The 
calendar period was divided into five-year-segments. Incidence was analysed by date 
and gender, using the age standardisation in Sweden, 1980-1984. We examined the 
changes in the annual age-standardized incidence rates by calculating the average 
yearly percentage change over a time period and straight lines were fitted to the 
standardised incidence by least squares regression. The slopes were estimated from 
these lines. We also analysed the incidence and population density in the 24 counties of 
Sweden by linear regression with the method of least squares. The definition of 
population density, as given by Statistics Sweden(146), is based on population centres. 
Survival rates were estimated with the life table method, taking censored observations 
into account. The cut-off date for follow up was 24th of February 2011. Tumour-
specific survival was analysed. 
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14.3 PAPER III 
14.3.1 Tumour samples 
We collected tumour samples (formalin-fixed paraffin-embedded blocks), clinical 
records and pathology reports from SNMMs that were reported to the SCR throughout 
Sweden diagnosed between 1986 and 2011. We excluded five samples because the 
sections contained too few tumour cells. Altogether 56 primary SNMMs were included 
and 12 of these cases were part of a previously published data set, Omholt and 
colleagues(23).  
 
14.3.2 Laser capture microdissection (LCM) and DNA extraction 
5 mm sections were cut from the paraffin blocks and placed on plain glass slides. The 
sections were deparaffinised with two washes of xylene, rehydrated in increasing 
concentrations of ethanol, rinsed with deionised water, shortly stained with 
haematoxylin, rinsed with deionised water and dehydrated in decreased concentrations 
of ethanol and two washes of xylene. Tumour cells were microdissected from sections 
by laser capture microdissection (LCM) using the Arcturus PixCell LCM System 
(Arcturus Engineering, Mountain View, CA, USA) according to the manufacturer’s 
recommendations. Samples were incubated overnight with proteinase K-enriched 
digestion buffer (PicoPure DNA Extraction KIT, Arcturus Engineering) to extract the 
DNAfrom the dissected cells. Proteinase K was then inactivated by heating samples at 
95°C for 10 min.  
 
14.3.3 Mutation analysis 
The DNA from the tumour cells was subjected to first and second PCR to amplify 
BRAF (exon 15), NRAS (exons 1 and 2) and KIT (exons 11, 13 and 17) genes. In the 
first PCR, the DNA was amplified in a 10 ml mixture reaction containing 2.5mM 
deoxynucleotide triphosphate, 5U/µl platinumTaq DNA polymerase (Invitrogen, 
Carlsbad, CA, USA), 50 pmol/µ1 of each primer, 10 x PCR buffer, 50mM MgCl2 and 
10 µg/µl bovine serum albumin. The PCR cycles: Initial denaturation at 95 °C for 3 
minutes, followed by 35 cycles of denaturation at 94 °C for 30 seconds and then 
annealing at 54-63 °C (depending on exon examined) for 30 seconds, and then 
elongation at 72 °C for 30 seconds; and a final extension at 72 °C for 10 minutes. The 
two microlitres of the first PCR reaction was used as DNA template for the second 
PCR. The conditions for the second PCR were similar to that of the first PCR except 
that the numbers of cycles were reduced to 20. The DNA was extracted and purified 
from agarose gels by using QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). 
Sequencing reactions were performed in a final volume of 20 µl using BigDye 
Terminator V1.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). 
The cycle sequencing conditions were as follows: 10 minutes at 95 °C, 25 cycles of 30 
seconds at 96 °C, 5 seconds at 50 °C and 4 minutes at 60 °C. The sequencing products 
were purified by ethanol precipitation, and automated DNA sequencing was performed 
by ABI PRISM3130xl Genetic Analyzer (Applied Biosystems). All mutations were 
confirmed by a second independent PCR and sequencing reaction. The primers used for 
amplification and sequencing are described in the supplementary table in paper II. 
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14.3.4 Statistical analysis 
We used Fisher’s exact test to correlate the mutation status with clinicopathological 
features. Using Wilcoxon rank-sum test we compared the age at diagnosis between the 
mutated and wild-type group. We estimated the overall survival from the date of 
diagnosis to the date of death or last follow-up (1 November 2012). Multivariate Cox 
regression model, Log-rank test and Kaplan–Meier graphs were used to assess the 
association of anatomical site with overall survival.  
 
  
 
14.4 PAPER IV 
14.4.1 Tumour samples 
We collected formalin-fixed paraffin-embedded tumour samples, clinical records and 
pathology reports of 54 SNMMs reported to the SCR from 1986 to 2011. The same 
patients were included in paper III (61 patients), except seven patients who were 
excluded because the sections left contained no tumour cells to analyse. Five samples 
were excluded since these sections contained too few tumour cells for analysis. 
Altogether 49 primary SNMMs were included in the study. The cut-off date for follow 
up was 31st of January 2013.  
 
14.4.2 Laser capture microdissection (LCM) and DNA extraction 
See 14.2.2. We used the same procedure as in paper II except for 20 patients whose, 
tumour cells were macrodissected and the DNA was extracted by using QIAamp DNA 
FFPE Tissue Kit (Qiagen, Valencia, CA). 
 
14.4.3 Mutation analysis 
The TERT promoter region from base pair position +65 to −278 was screened for 
mutations using PCR and direct Sanger sequencing. Genomic DNA was subjected to 
initial and subsequently nested PCR to amplify TERT promoter regions. The first and 
second PCR was performed as described in 14.2.3.  
The primers used for amplification and sequencing of TERT promoter were as 
described by Rachakonda and colleagues(147)(see Supplementary table 1 in paper IV). 
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15 RESULTS 
15.1 PAPER I 
15.1.1 Frequency of sinonasal malignancies 
3221 patients with non-lymphoid malignant tumours of the sinonasal cavity and the 
paranasal sinuses was identified from the SCR. The majority were in the sixth decade 
or older when diagnosed. Patients with SNMM had the highest average age at diagnosis 
of 71.7 years in contrast to those with adenoid cystic cancer whose mean age at 
diagnosis was the lowest, 62.5 years.  
 
The most common diagnosis was SCC followed by adenocarcinoma and SNMM. Of 
the patients diagnosed SCC 65% were male, however, for SNMM and adenoid cystic 
cancer, women predominated (55% and 53% respectively).  
 
In total, 50.5% of the tumours involved the nasal cavity, and 31.7% affected the 
maxillary sinus. The remaining tumours were localized in the other sinuses or had a 
spread growth. Over the years we reviewed an increasing proportion of tumours 
originated in the nasal cavity compared to tumours arising in the maxillary sinuses. 
Individuals with SNMM had a higher frequency of tumours located in the nasal cavity 
compared to those with SCC. 
 
15.1.2 Incidence of sinonasal malignancies 
For SNM the overall incidence rate per 100 000 decreased from 1.19 in the 1960´s to 
0.86 in the 2000´s. SCC as well as undifferentiated carcinoma decreased whereas the 
incidence of adenocarcinoma increased in the beginning of the study period and 
decreased at the end. SNMM is the only sinonasal malignancy that has increased in 
incidence during the study period (from 0.04 1960-1964 to 0.15 2005-2010).  
 
15.1.3 Survival of patients with sinonasal malignancies 
The women had a 4 % lower mortality rate than men, but the difference was not 
statistically significant (p=0.48). During the study period, the length of survival 
improved over time for both genders regardless of the histological diagnosis.  
 
Patients with adenocarcinoma and SCC had a 5-year survival of 56% and 46% 
respectively. SNMM and undifferentiated carcinoma yielded a poorer prognosis, 27% 
and 37% 5-year survival, respectively. Patients with adenoid cystic cancer had the best 
5-year prognosis, 58%. Moreover, patients whose tumours originated from the nasal 
cavity had a better prognosis (mean overall survival 84.2 months) than patients with 
tumours localized in the maxillary sinuses (mean overall survival 55.2 months) 
(p<0.0001).  
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15.2 PAPER II 
15.2.1 Patients 
Of the 186 patients represented here, 55% (102) were women and 45% (84) men. Their 
ages at diagnosis ranged from 31 to 93 years, with a median age of 72. All patients 
were Caucasians (as reported by the medical records). 168 of the 186 SNMM were 
classified according to TNM and Ballantyne stage. 18 patients had insufficient data for 
classification. 92.9% of the SNMM tumours presented in Stage I.  
 
The mean age-specific incidence of SNMM increased with age peaking after the 
eightieth year in both genders. The age-standardized incidence increased significantly 
for both genders during the investigated time period. For females the average annual 
age-standardized incidence per million population increased from 0.54 1960-1964 to 
1.08 during 1995 - 2000. The incidence increased more rapidly among males (0.25 to 
0.67 per million per year) compared to females, however this difference was not 
statistically significant. 
There was no correlation between population density and the incidence of SNMM. The 
island of Gotland, showed an unquestionable higher incidence of SNMM than all other 
counties. 
 
15.2.2 Tumour site 
44.1% of the tumours involved the nasal cavity, where the inferior turbinate followed 
by septum were the most frequent sites. About ¼ of the tumours affected the sinuses. 
34.4% of the patients, was indeterminate due to growth both in the nasal cavity and 
sinuses or because the original site was not specified in the medical records. 
 
15.2.3 Clinical and pathological features 
The most frequent symptom at diagnosis was epistaxis followed by nasal obstruction. 
According to the medial charts 70.9% of the patients presented with an amelanotic 
tumour and 34.8%, initially had amelanotic polyps. 41.1 % presented as ulcerated 
tumours and only 4.6% of those manifested as macroscopically pigmented. Patients 
present with more advanced disease over the study period. Among the patients 
classified as Stage I (156 patients), 28.8% developed recurrent disease within one year 
of diagnosis. 57.8% of the recurrent disease remained localized. 17.8% developed 
regional metastases and 24.4% distant metastases. The median time to local recurrence 
was 23 months, and times to regional and distant metastasis were 11 and 8 months, 
respectively.  
 
15.2.4 Histopathology 
Over 1/5 of the patients were mis-diagnosed initially (e.g. olfactory neuroblastoma, 
lymphoma, poorly differentiated SCC or sarcoma). The mis-diagnoses patients were 
usually based on the small size of patients’ biopsies. The initial diagnosis was revised 
after secondary extended surgery, when more tumour material was available for 
analysis. 
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15.2.5 Treatment 
Surgery alone was the most common primary treatment performed in 53.1% of the 
patients, followed by surgery combined with pre- or postoperative radiotherapy in 
32.0%. Only 2.7% received radio-chemotherapy combined with surgery. 17.8% of the 
patients underwent local excisions, whereas procedures for 47.4% were done according 
to Denker. Another 26.7% received a total maxillectomy, and 8.1% underwent 
maxillectomy and exenteration. In 12.2%, treatment was restricted to chemotherapy, 
radiation, or partial resection of the tumour, with palliative intent, or no antitumoural 
treatment. In about 1/5 of the patients, information regarding treatment was missing. Of 
the four patients in Stage II, one underwent neck dissection surgery and postoperative 
chemo/radiotherapy. The other 3 patients received palliative treatment as well as the 
patients in Stage III. 
 
15.2.6 Survival 
The follow-up time ranged from 0 to 283 months for patients who eventually died and 
148 – 172 months for living patients. The tumour-specific, five-year survival rate was 
20.4% for all patients. Women had significantly better survival rates than men 
(p=0.038). Patients over 60-years at diagnosis died significantly earlier than younger 
patients (p=0.040). However, there was no difference in the length of survival five 
years after diagnosis. Patients with epistaxis had a better prognosis than those with only 
nasal congestion (p=0.046). The choice of primary treatment for patients in Stage I did 
not have a significant impact on outcomes in terms of time to recurrent disease or 
tumour-specific survival. Survival increased significantly irrespective of therapy during 
the study-period of this survey(p=0.024). 
 
15.3 PAPER III 
15.3.1 Clinicopathological characteristics 
The tissues examined were derived from 56 patients, 35 females and 21 males whose 
collective median age at diagnosis was 76 years. Of these, 34 tumours were located in 
the nasal cavity and 22 in the paranasal sinuses (10 in the maxillary sinuses, 6 in the 
ethmoid sinuses and 6 tumours invaded surrounding structures: 4 involved the orbit; 
one the skull base and another spread to the retromaxillary infratemporal fossa).  
 
15.3.2 Mutation analysis 
The analysis showed that 21% (12 of 56)) of the tumours harboured KIT, NRAS or 
BRAF mutations. KIT mutations were detected in 4% (2 of 56) of the cases. Both KIT 
mutations were identified in exon 11, L576P, however no mutations were observed in 
exons 13 and 17. According to a previous study by Omholt and colleagues(23) the 
frequency of KIT mutations in vulvar melanomas (35%) was much higher. NRAS 
mutations were identified in 14% (8 of 56) and BRAF mutations in 4% (2 of 56). Four 
of the NRAS mutations were found in exon 1 (G12C, G12D, G12A and G13D) and four 
in exon 2 (Q61K, Q61R and Q61H (n¼2). Of the two BRAF mutations one was V600E 
and one V600K change.  
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15.3.3 Association of mutations with clinicopathological features 
The tumours with mutations had a higher frequency of paranasal localization compared 
to the wild-type tumours, which were more frequently found in the nasal cavity 
(p=0.045). However there was no difference between the mutated and the wild-type 
group when comparing gender, age at diagnosis, ulceration or tumour pigmentation. 
 
15.3.4 Survival 
The overall survival was significantly associated with anatomical site, clinical stage and 
age at diagnosis. Patients with tumours arising in the nasal cavity had a significantly 
better prognosis than those with tumours in the paranasal sinuses (median survival 
months, 39 vs 16 p=0.027). After adjusting for age at diagnosis, gender, ulceration, 
pigmentation and clinical stage, this effect remained significant (p=0.001). There was 
no association with the overall survival or differing mutation status. 
 
15.4 PAPER IV 
15.4.1 Clinicopathological characteristics 
The samples analysed were from 49 patients, 31 females and 18 males whose overall 
median age at diagnosis was 76 years. Of these tumours, 30 were located in the nasal 
cavity and 19 in the paranasal sinuses (9 in the maxillary sinuses, 6 in the ethmoid 
sinuses and 4 that had invaded the surrounding structures: 3 involved the orbit; one 
spread to the retromaxillary-infratemporal fossa). When diagnosed, most of these 
patients were in stage III according to UICC 7 th edition. Only one patient had lymph 
node metastases in the neck region, and none had distant metastases at diagnosis. 
 
15.4.2 Mutation analysis 
Of the 49 primary SNMMs analyzed, 4 (8 %) harbored TERT promoter gene mutations 
and 5 (10 %) were wild type. All the others, 40 (82 %), had the -245G>A alteration, a 
known single nucleotide polymorphism (SNP), rs2853669 (Horn et al, 2013; 
Rachakonda et al, 2013). Among the identified promoter mutations two had the same 
mutations -124G>A (1295228) and -125G>A (1295229), one had the -146G>A 
mutation (1295250) and one 57T>G (1295161). All these mutations have been reported 
to create binding motifs for ETS/TCF, and are thus likely to be of functional 
significance(137, 139, 147). 
 
15.4.3 Mutations in relation to clinicopathological features 
Owing to the small number of patients with mutated tumours, no statistically valid 
comparison was possible between these and the remaining patients. Three females and 
one male were recorded among the patients with TERT promoter gene mutations. Two 
tumours were localized in the nasal cavity and 2 in the maxillary sinuses. The youngest 
patient was diagnosed at the age of 52 years and the oldest at 92 years. The survival 
range varied from 19-121 months. 
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16 DISCUSSION 
The aim of this thesis was to investigate the epidemiology, clinicopathological features, 
pathogenetical aspects and prognostic factors for SNMM in Sweden and also the 
epidemiological aspects of SNM. Our unique material for both SNM and SNMM is one 
of the largest population-based sets of tumour studies of its kind. The results of our 
studies have enlightened the relatively poorly investigated patient categories SNM and, 
particularly, SNMM.  
 
16.1 PAPER I 
In this study of SNM, which embodied one of the largest population-based studies in 
recent years, we found an overall decreasing incidence of SNM in Sweden during the 
study period 1960 through 2010. Interestingly, SNMM is the only category of SNM 
tumours that has increased numerically to a significant extent during in that time 
period.  
SCC was the most frequent SNM followed by adenocarcinoma during the study period. 
However, when comparing incidence data from 1960 and 2010, SCC was still the most 
frequently found tumour followed by SNMM, which was rare in 1960. An increasing 
incidence of SNMM was also observed in other recent studies(148, 149). The 
differences in distribution over time of the various histological types might reflect an 
actual change in relative incidence of different histological types but also denotes 
imoroved diagnostic methods. New diagnostic tools, such as immunohistochemical 
markers, have increased the accuracy of identifying certain tumours, whereas many of 
the “undifferentiated” tumours in 1960 now are likely to yield histologically specific 
diagnosis.  
 
An association between SNMs and exposure to inhaled carcinogens such as wood dust 
has been reported in several investigations in the late 1960s and early 1970s(6, 7). Most 
notably, the adenocarcinoma is particularly strongly related to exposure to leather dust 
or dust from hard wood(8, 9). Moreover, excessive air pollution has been described as 
an etiological factor for SNM in general(9, 12). Therefore, the decreasing incidence in 
most histological types of SNM may reflect better working conditions and reduced air 
pollution over the years. Furthermore, the decreasing incidence of SCC might also be 
correlate with reductions in habitual smoking that we know is a crucial contributor to 
its pathogenesis(14).  
 
The majority of tumours included here originated in the nasal cavity, as in other similar 
studies(2, 3, 14). We also found that an increasing proportion of tumours arose first in 
the nasal cavity compared to the maxillary sinuses for all SNM during this study 
period, in agreement with outcomes in a recently published article by Youlden and 
colleagues(2). Perhaps patients’ and doctors’ delays in the 1960s resulted in a 
misclassification of tumour, whereas by 2010, better diagnostic tools and earlier 
diagnoses provided more reliable information about tumours’ sites of origin.  
 
Some of the tumours in the nasal cavity, especially SCC and SNMM, may be 
misclassified and as they might, instead, have originated from the skin in vestibulum 
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nasi. Finally, differing the sites of origin for tumours found in the nasal cavity, ethmoid 
sinuses and maxillary sinuses would have been far more difficult before our modern 
diagnostic tools were available (CT and MRI).  
 
We have found no significant improvement in the survival times of patients with SNM 
over the last 50 years. However, tumours originating in the nasal cavity enabled 
significantly longer survival periods compared to those at other locations, presumably 
because nasal cavity tumours present earlier with such straightforward symptoms as 
nasal blockage or epistaxis and are, therefore, diagnosed sooner. Yet, there was a slight 
increase in overall relative 5-year survival. Surprisingly, the new treatment strategies 
and modern diagnostic tools, which facilitate greater precision of therapy, have not 
significantly improved treatment outcomes. Our data do not show any clearcut 
difference in 5-year survival between men and women. Others have confirmed this 
conclusion in a long-term survival analysis(150), where survival was supposedly linked 
to stage at diagnosis, extent of spread and onset of symptoms rather than gender. 
 
The strength of this present overviews, which is the largest European population-based 
study on SNM of its kind, is its basis on data from the nationwide Swedish cancer 
registry with its uniquely extensive coverage. Furthermore, our study is the first to 
describe the trends in incidence and survival of sinonasal malignancies in Sweden over 
a long period. The weakness is that, due to the rarity SNM and even more in some of 
the histological subtypes, conclusions from this material may be difficult to draw.  
   
16.2 PAPER II 
We found that the incidence of SNMM in Sweden has increased significantly from 
1960 through 2000, although not at the same rate as CMM in the same time period. The 
reasons for this increased incidence are unknown, but the impact of improved 
diagnostic methods cannot be ruled out. New diagnostic tools such as 
immunohistochemical markers have increased the accuracy of identifying SNMM. 
Since over 30% of the patients with SNMM display non-pigmented tumours, 
identification of these markers is important for obtaining the correct diagnosis. In the 
samples assessed here, we found that about 70% manifested clinically amelanotic 
melanomas. We also documented that about 20% of the patients were primarily 
misdiagnosed as bearing low- or undifferentiated malignancies. We think that a 
reduction of misdiagnosis is a much too simple an explanation when there are a 
significant difference in incidence between males and females. There is a higher overall 
incidence of SNMM for females than males, but with a more rapid increasing incidence 
among males. In contrast, a female predominance was not seen in other sinonasal 
malignancies, where there is a higher incidence for men (except for adenoid cystic 
cancer, which also predominated in women, see paper I). However, the incidence of 
CMM in Sweden was similar in both genders(40). 
 
We did not find any difference between the incidence of SNMM in either sparsely vs 
densely populated geographic regions of Sweden, which argues against a causative 
impact of air pollution in urban areas. Air pollution is otherwise an important factor to 
consider in the genesis of sinonasal malignancies. Consequently, a report from Mexico 
City described an increase of paranasal malignancies (including SNMM) suggesting 
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that the heavy air pollution could be responsible(12). Furthermore, inhaled carcinogens 
are known to induce SNM and SNMM. Environmental carcinogens and drugs (e.g. 
aflatoxin B1, benzidine, and polycyclic hydrocarbons, such as dimetylbenzanthracene 
and benzopyrene) are filtered by and conjugated to melanins, sometimes over a long 
time period(61). Human melanocytes are known to be capable of metabolizing the 
carcinogen benzopyrene and their metabolites that might be involved in the 
development of SNMM(62).  
 
In the patient material examined here, the nasal septum and the turbinates were the 
most commonly affected subsites, which also suggests that an inhaled carcinogens 
could be a cause of tumour formation, since most inhaled air passes through the nasal 
cavity during normal breathing. Occupational exposure to formaldehyde may also 
contribute to SNMM as is suggested by Holmström and colleagues(63). Information on 
possible occupational and environmental factors was, unfortunately not available in our 
material.  
 
For about 1/3 of the patients included here, the site of origin was not specified in the 
medical records because tumour growth was present in both the nasal cavity and the 
paranasal sinuses or because the original site was indeterminate. Presumably, patients’ 
and/or doctors’ delay in seeking diagnosis resulted in identifying tumours only at 
advanced stages so that the original location was difficult to determine. In the later part 
of the investigated time period more advanced tumours were identified. Today’s more 
advanced techniques, including CT scanning, MRI, and PET/CT scanning, were not 
available during this study’s initial period and might, therefore, account for the 
apparent increase of more advanced tumours over the years. 
 
The prognosis is poor for SNMM patients of both genders. However, women had 
significantly better survival rates than men and the same gender-associated difference 
in survival has also been reported for patients with ano-rectal melanomas in 
Sweden(48). This gender difference is also described for CMM in Sweden(113).  
 
During the first five years after diagnosis the older patients had a more lethal disease 
compared to younger patients. However, there was no difference in survival times five 
years or more after diagnosis between the age groups. Explanations for this calculation 
might be an age-related decline of immunologic defence or a choice not to institute 
standard therapy because of an elder’s weak physical condition or refusal of treatment.  
 
The nonspecific initial symptoms of SNMM, such as nasal congestion are probably the 
reason for a patient not to seek medical care in time. Accordingly, patients with the 
obviously more alarming early symptom of epistaxis undoubtedly sought medical 
examination sooner and thus had a better prognosis.  
 
The SNMM tumours appeared in the majority of the cases as amelanotic and is 
frequently described as an amelanotic polyp, often mistaken for a benign lesion. To 
avoid misdiagnosis a solitary polyp in the nasal cavity always requires a biopsy for 
histopathological investigation. 
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Metastases to the regional lymph node at presentation were uncommon in our study 
(3.3%) compared to SCC(10%)(51) and to SNM in general(3). However, distant 
metastases were more frequents, which is due to the greater haematogenous 
dissemination of melanomas. 
 
In this series the preferred treatment for patients with SNMM in Stages I-II (according 
to Ballantyne) was complete surgical tumour excision. The different treatment 
strategies did not have any impact on time to recurrence or disease-specific survival. 
However, the small numbers of patients, selection bias and that there were no 
systematic treatment or follow up for these patients makes it difficult to draw any firm 
conclusions on the outcome of different therapeutic strategies. 
 
A study by Lund and colleagues in 2012, reported that radiotherapy did not improve the 
local control or survival of patients with SNMM. Those authors also found that cervical 
metastases were associated with a dramatically worse outcome(26). In contrast, another 
study reported that a higher total dose of postoperative radiotherapy improved loco 
regional control(98). Moreover, other reports emphasize the advantage of adjuvant 
radiotherapy(108, 109).  
 
One must be aware of that when rare neoplasms, such as SNMM, are studied the 
analysis may be incomplete. However, our study examining many cases in a national 
population-based series, provides a far better opportunity to give us information on 
clinical features that the individual case study or case series may disregard.  
 
16.3 PAPER III 
Few published reports on SNMM exist, and those available include mutational data on 
only small numbers of tumours. In this study, the largest of its kind to our knowledge, 
we screened SNMM tumours for the most commonly mutated oncogenes in CMM. We 
found that KIT mutations are rare compared to other mucosal sites where for example 
vulva melanoma harbour a much higher frequency KIT mutation (35 %), reported by 
Omholt and colleagues(23). In a recent study by Schoenewolf and colleagues on 
sinonasal and vulvovaginal melanomas, no KIT mutations were found in 12 sinonasal 
tumours compared with 5 mutations in 11 vulvovaginal tumours (45%)(151). 
Moreover, Beadling and colleagues found a lower frequency of KIT mutations in 
mucosal melanomas of the head and neck (3 of 36; 8%) when compared with 
melanomas of the anorectum/vulva/vagina (4 of 9; 44%)(96).  
 
BRAF mutations in mucosal melanoma are generally rare in mucosal melanomas and 
do not seem to vary significantly between different sites(23). In our study, BRAF 
mutations were also rare, which is similar values for other mucosal melanomas at other 
sites such as the vulva, vagina and ano-rectum(23, 88).  
 
The frequency of NRAS mutations where higher compared to KIT- and BRAF 
mutations. The NRAS mutations seem to be corresponding to that in CMM(80, 122, 
123). Yet, the types of NRAS mutations in SNMM differ from the types that are most 
commonly detected in CMM. Only two of eight NRAS mutated SNMM tumours 
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contained the two most common NRAS mutations in CMM(152). The different patterns 
of NRAS mutations in SNMM are consistent with other aetiology than UV-radiation. 
 
We found that melanomas originating in the paranasal sinuses have a higher mutation 
frequency than those originating in the nasal cavity. Furthermore, patients with disease 
located in the paranasal sinuses had a worse prognosis than those with tumours located 
in the nasal cavity, which has also been reported in other studies(92, 153). The poor 
prognosis for those within paranasal tumours might be the consequence of more 
advanced tumour stage, as in six of these patients had tumours invaded the surrounding 
structures.  
 
There were no difference in overall survival between patients with mutated melanomas 
and those with wild-type melanomas; however the power to detect a difference is low, 
since the numbers of tumours with mutations is small. In a previous study, KIT 
mutations as well as NRAS mutations were associated with poor survival(23). Another 
report has shown that KIT mutations adversely affected survival for both mucosal and 
CMM(126).  
 
The relatively low proportion of KIT and BRAF mutations in SNMM tumours indicate 
that only a few SNMM patients may benefit from therapy with KIT- and BRAF-
inhibitors. However, higher frequency of NRAS-mutated tumours suggest that it might 
be worth to perform studies on SNMM patients using MEK inhibitors, which have 
shown promising results in CMM with NRAS mutations(32).  
 
 
16.4 PAPER IV 
In this study we analysed a large number of primary SNMM for TERT promoter gene 
mutations, which are common in CMM(137, 139). To our knowledge this has not been 
analysed specifically in SNMM previously and never in as large a study as this one. We 
identified TERT promoter gene mutations in 8 % of the tumours, but because the 
number of cases was small, we could not analyse clinicopathological features in 
relation to the mutations. Three of the tumour associated mutations  
(-124G>A, -125G>A and -146G>A) are known to generate binding motifs for Ets 
transcription factors, resulting in increasing transcriptional activity from the TERT 
promoter by two- to four-fold(137). The  -57T>G mutation is also known to increase 
transcriptional activity in the same way but only by 1.5-fold(139). The majority of the 
patients had the SNP rs2853669 (-245A>G). In previous studies this polymorphism 
was reported to disrupt an ETS binding site and was associated with low telomerase 
activity in patients with non-small cell lung cancer(154). 
Rachaconda and colleagues have also found a reduction in promoter activity in 
urothelial carcinoma with the same SNP, and suggested that the rs2853669 
polymorphism might have a protective effect on survival and recurrence(147). 
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17 CONCLUSION 
 
The main conclusions are: 
 
The incidence of sinonasal malignancies in Sweden have decreased from 1960 to 2010. 
However in the same time period sinonasal malignant melanoma incidence has 
increased and is now the second most common SNM. 
  
There was no significant improvement in survival times for individuals with SNM over 
the last 50 years despite better diagnostic tools and treatment options. 
 
The incidence of SNMM was significantly higher among women than men.  
Despite the poor prognosis, although better for women than for men, the five-year, 
tumour-specific survival rate improved significantly for both genders during the period 
1960 through 2000. 
 
The SNMM patients with epistaxis as their initial symptom had a significantly better 
prognosis than those with only nasal congestion. 
 
For the majority of the SNMM patients, the tumour appeared as a clinically amelanotic 
growth and often as an amelanotic polyp. This fact stresses the importance of biopsy 
for histological investigation when diagnosing a solitary polyp or growth in the nasal 
cavity. 
 
The most common site of origin was the nasal cavity for both SNM and SNMM. For 
SNMM the most common site in the nasal cavity was the inferior tubinate followed by 
the nasal septum. 
 
Patients with SNM and SNMM originating from the sinuses had a worse prognosis 
than those with tumours originating from the nasal cavity. 
 
The proportion of advanced tumours increased for SNMM over the study period 1960 
through 2000. The reason for this is not clarified, but may be due to more sophisticated 
diagnostic technology emerging over the years. 
 
In our study, the different treatment strategies did not affect the time to recurrence or 
disease specific survival for SNMM.  
 
KIT, NRAS and BRAF mutations occurred at low frequencies in SNMM, and the 
frequency of KIT mutation in mucosal melanoma mutations vary significantly between 
different anatomical sites.  
 
Tumours from the paranasal sinuses have a higher frequency of KIT, NRAS and BRAF 
mutations than tumours from the nasal cavity. 
 
  40 
TERT promoter mutations occurred at a moderate frequency in SNMM. We suggest 
that SNMM tumours should be included in molecular characterizations, since these 
alterations are likely be therapeutic targets in the near future.  
 
 
 
 
 
 
 
 
 
  41 
18 FUTURE PERSPECTIVES 
 
We found an increasing incidence of SNMM in Sweden from 1960 through 2010. The 
cause of this increase is at present unknown. Research has indicated that inhaled 
carcinogens and air pollution may be involved in the development of melanomas. 
However, although we have seen less air pollution and better working conditions over 
the years, our findings do not reflect those improvements. The aetiological factors still 
remain unknown and remain in need of future investigation.  
 
There are relatively low frequencies of KIT, NRAS and BRAF mutations as well as a 
low frequency of TERT promoter gene mutation in SNMM. This indicates that SNMM 
harbours other mutations yet to be discovered.  
 
Clearly, since the prognosis is so poor for patients with SNMMs, finding new treatment 
options continues to be of primary importance. But as one must acknowledge, 
identifying the pathogenesis is still an urgent research objective. Toward that end, 
revealing other driver mutations involved in the development of SNMM would benefit 
appreciably from whole genome mutation analysis. 
 
Unfortunately, the new treatment strategies and modern diagnostic tools have not 
significantly improved treatment outcome for SNM; therefore, better options must be 
devised. Only when large-scale comparisons of diverse outcomes for SNM become 
available can we evaluate the optimal therapy for these patients. 
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